Company news: Teva, Merck and BMS
Teva kicks off a succession plan early, and Merck launches Phase II trials of two all-oral hepatitis C regimens.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.